- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07705594
LuX-Valve Plus System for Severe or Greater Tricuspid Regurgitation
A Prospective, Multicenter, Randomized Controlled Clinical Trial to Evaluate the Safety and Efficacy of a Transvenous Artificial Tricuspid Valve System in Patients With Severe or Greater Tricuspid Regurgitation
This clinical trial aims to evaluate the safety and effectiveness of the Transvenous Artificial Tricuspid Valve System, LuX-Valve Plus System, Jenscare Scientific Co., Ltd. The study population consists of high-risk patients with severe or greater tricuspid regurgitation (TR) who are ineligible for surgical intervention and have demonstrated inadequate response to optimized medical therapy (OMT).
This is a prospective, multicenter, randomized controlled trial. A total of 111 subjects who meet all inclusion criteria and none of the exclusion criteria will be enrolled. Participants will be randomized in a 2:1 ratio to one of the following groups:
Treatment Group: Transvenous Artificial Tricuspid Valve System implantation + OMT Control Group: OMT alone
All subjects will undergo serial follow-up assessments pre-treatment, during the treatment period, and post-procedure at 30 days, 3 months, 6 months, 1 year, and annually through 2-5 years. A summary report will be submitted to the regulatory authority at the 6-month time point.
Subjects in the treatment group will have one extra follow-up visit at 7 days ± 3 days post-procedure or prior to discharge (whichever occurs first).
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Chine, 200032
- Zhongshan hospital, Fudan university
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Age ≥ 65 years
- Severe or greater TR (TR ≥ 3+ / 4+ by echocardiography)
- High surgical risk or inoperable per heart team (TRI-SCORE ≥6, STS ≥8%, EuroSCORE II ≥3%, etc.) AND symptomatic despite GDMT (≥1 month diuretics, stable regimen for ≥2 weeks)
- Suitable for TTVR per heart team
- NYHA III-IV
- Signed ICF and willing to comply with follow-up
Exclusion Criteria:
- Anatomy unsuitable for device procedure
- LVEF < 50%
- SPAP > 60 mmHg by TTE (unless RHC confirms ≤60 mmHg)
- Aortic/mitral/pulmonary valve disease requiring surgery
- Prosthetic valve replacement within 6 months or moderate/severe dysfunction
- Ebstein anomaly or RV dysplasia
- RVOT obstruction or intracardiac mass
- Active endocarditis within 90 days, or antibiotics for infection within 14 days
- CV/cardiac/cervical surgery within 30 days
- Stroke within 90 days
- Unable to tolerate anticoagulation/antiplatelet therapy
- eGFR < 30 mL/min/1.73m² or on RRT
- MELD-Albumin ≥ 12
- Severe respiratory dysfunction (unsuitable for general anesthesia)
- Active GI bleeding/ulcer within 90 days
- Cardiogenic shock or hemodynamic instability within 30 days
- Untreated severe CAD or ACS within 30 days
- Life expectancy ≤ 1 year
- Known allergy to device components or study drugs
- Pregnancy or lactation (or planned pregnancy)
- Enrolled in another interventional trial (not reached primary endpoint)
- Other conditions deemed unsuitable per investigator
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Treatment Group
LuX-Valve Plus System+OMT
|
Transvenous tricuspid valve replacement with Lux-Valve Plus System in patients with severe or greater Tricuspid Regurgitation despite optimal medical therapy (OMT)
|
|
Autre: Control Group
OMT only
|
Optimal medical therapy (OMT) as the control group for patients with severe or greater tricuspid regurgitation
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence rate of composite endpoint events
Délai: 6 months post-treatment
|
Percentage (%) of participants achieving composite clinical success at 6 months. Composite clinical success is defined as meeting all of the following criteria:
|
6 months post-treatment
|
|
Rate of Major Adverse Events (MAE)
Délai: 30 Day Post-treatment
|
The major adverse event (MAE) rate is defined as the occurrence of any of the following: Cardiac death Myocardial infarction Stroke New-onset renal failure requiring renal replacement therapy after the procedure Major bleeding (Grade ≥3b according to TVARC) Tricuspid valve re-intervention Device puncture site and vascular access complications Major cardiac structural complications Device-related pulmonary embolism Arrhythmia or conduction block requiring permanent pacemaker implantation |
30 Day Post-treatment
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CP-TVS02-C2401
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .